快速药敏指导重症革兰阴性菌血流感染早期靶向治疗
该回顾性队列研究纳入133例重症革兰阴性菌血流感染成人患者,比较快速药敏试验(RAST,37例)与常规药敏试验(AST,96例)的真实临床影响。RAST组30天全因死亡率10.8%,AST组31.3%(P=0.015);RAST组早期有效治疗率86.5%,AST组45.8%(P<0.001)。Cox回归显示RAST指导管理(HR=0.16,95%CI 0.04-0.62)与早期有效治疗(HR=0.51,95%CI 0.19-0.94)独立关联生存。
要点
- RAST组30天死亡率10.8%,低于AST组31.3%(P=0.015)
- RAST组早期有效治疗率86.5%,高于AST组45.8%(P<0.001)
- RAST指导管理独立关联生存(HR=0.16,95%CI 0.04-0.62)
核心结论
- 在重症革兰阴性菌血流感染患者中,RAST可能有助于优化抗菌治疗,尤其在高耐多药背景下。
研究设计与样本
- 回顾性观察性研究,纳入133例成人革兰阴性菌血流感染患者,按药敏策略分为RAST组37例与常规AST组96例。
主要发现
- RAST组30天全因死亡4/37(10.8%),AST组30/96(31.3%),P=0.015。
- RAST组早期有效治疗32/37(86.5%),AST组44/96(45.8%),P<0.001。
- 临床失败RAST组0/37,AST组20/96(20.8%),P=0.003。
- 平均ICU住院时间RAST组30.3±22.9天,AST组36.9±25.6天,P=0.17。
- Cox回归中RAST指导管理HR=0.16(95%CI 0.04-0.62),早期有效治疗HR=0.51(95%CI 0.19-0.94),均独立关联生存。
临床怎么用
- 对重症革兰阴性菌血流感染患者,可考虑采用RAST以促进早期有效抗菌治疗并改善生存。
局限性
- 为单中心回顾性观察性研究,样本量有限(RAST组37例),存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study assessed the real-world clinical impact of rapid antimicrobial susceptibility testing (RAST) compared with conventional susceptibility testing (AST) in critically ill patients with Gram-negative bloodstream infections (GNB BSIs), focusing on early optimization of therapy and clinical outcomes in a high multidrug-resistant (MDR) setting. METHODS: We conducted a retrospective, observational study including adult patients with GNB BSIs who were stratified according to the susceptibility testing strategy used (RAST or conventional AST). The primary outcome was 30-day all-cause mortality. Secondary outcomes included administration of early active antimicrobial therapy, clinical failure and length of both intensive care unit (ICU) and hospital stay. RESULTS: A total of 133 patients were included (RAST: 37; AST: 96). Thirty-day mortality was observed in 4/37 patients (10.8%) in the RAST group and in 30/96 (31.3%) in the AST group (P = 0.015). Early active therapy was administered to 32/37 (86.5%) RAST patients versus 44/96 (45.8%) in the AST group (P < 0.001). Clinical failure occurred in 0/37 RAST patients versus 20/96 (20.8%) AST patients (P = 0.003). Mean ICU stay was 30.3 ± 22.9 days (RAST) versus 36.9 ± 25.6 days (AST), P = 0.17. In Cox regression analysis, RAST-guided management (HR = 0.16, 95% CI 0.04-0.62) and early active therapy (HR = 0.51, 95% CI 0.19-0.94) were independently associated with survival. CONCLUSIONS: RAST may represent a valuable tool to optimize antimicrobial therapy in critically ill patients with GNB BSIs, particularly considering the increasing prevalence of MDR pathogens.
引用
- Rotundo S, Russo A, Morena R, et al. Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study. J Antimicrob Chemother. 2026. PMID: 41700715. doi:10.1093/jac/dkag056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。